In recent years, biomarkers have shown significant promise in helping decision‐making in
drug development. Systemic lupus erythematosus (SLE) is a complicated and highly …

Systemic lupus erythematosus (SLE) is a complex and highly heterogeneous disease. By
now, no novel drug has been approved by the US FDA in the past 50 years, except …

Objective Trials of new systemic lupus erythematosus (SLE) treatments are hampered by the
lack of effective outcome measures. To address this, we developed a novel Lupus …

Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting
different organs. The improved knowledge of the disease's pathogenesis has contributed to …

Introduction: Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting
many different organ systems. Although disease manifestations are varied across the lupus …

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease that
represents a great challenge for current therapy as well as new drug development (1, 2) …

Introduction: In the last decade, the development of a number of potential drugs for lupus
that target the pathogenesis of the disease at different levels has been witnessed. Despite a …

Belimumab is the first biologic approved for patients with systemic lupus erythematosus
(SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or …

Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease driven
by genetic, hormonal, and environmental factors. Despite the advances in diagnostic and …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder with multiple organ
involvement. B-lymphocyte activity plays a pivotal role in the development and course of the …